Merrion Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Merrion Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,250	Closed	-$558K	–	112
2026 Q1	$558K	Hold	1,250	–	–	0.3%	69
2025 Q4	$567K	Hold	1,250	–	–	0.31%	64
2025 Q3	$490K	Hold	1,250	–	–	0.28%	69
2025 Q2	$557K	Hold	1,250	–	–	0.36%	56
2025 Q1	$606K	Buy	1,250 +245	+24%	+$114K	0.44%	54
2024 Q4	$405K	Hold	1,005	–	–	0.28%	71
2024 Q3	$467K	Hold	1,005	–	–	0.31%	67
2024 Q2	$471K	Buy	1,005 +5	+0.5%	+$2.17K	0.32%	59
2024 Q1	$418K	Hold	1,000	–	–	0.3%	65
2023 Q4	$407K	Buy	+1,000	New	+$369K	0.32%	63

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Merrion Investment Management's VRTX Position: Q2 2026 in Review

Merrion Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 1,250 shares — an estimated $558K sold.

Merrion Investment Management first reported a position in VRTX in Q4 2023 and held it in 10 quarters. The position peaked at $606K in Q1 2025. 734 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Merrion Investment Management reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Merrion Investment Management sold 1,250 Vertex Pharmaceuticals shares in Q2 2026, an estimated $558K.
Merrion Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 10 quarters.
Merrion Investment Management's Vertex Pharmaceuticals position peaked at $606K in Q1 2025.
734 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Merrion Investment Management's 13F filing for Q2 2026, filed 13 Jul 2026.